智通财经网·2025-08-18 06:13Core Viewpoint - The report from Credit Lyonnais indicates a strong sales momentum for JD Health, leading to upward adjustments in net profit forecasts for 2025 and 2026 by 15% and 13% respectively, while maintaining an "outperform" rating [1] Financial Performance - JD Health's revenue for the first half of the year increased by 24.5% to 35.3 billion RMB [1] - Adjusted EBIT rose by 57% to 2.5 billion RMB [1] - The second quarter revenue growth was 24%, supported by strong performance during the 618 shopping festival and significant user growth [1] Sales Growth Drivers - The anticipated revenue growth of 16% year-on-year in the second half of 2025 is primarily driven by over 25% growth in pharmaceutical sales [1] - The sales of health supplements are expected to see high double-digit year-on-year growth [1] - The shift in demand for original factory drugs from hospitals to outpatient settings has contributed to the increase in pharmaceutical sales [1] Investment Focus - The company continues to invest in O2O (online-to-offline) business, offline pharmacies, and AI technologies [1] - Adjusted EBIT is expected to remain stable year-on-year due to these ongoing investments [1]